Eagle Will Be Last Firm To Bypass FDA's Orphan Drug Exclusivity Requirement
Executive Summary
Court orders US FDA to award Bendeka seven years of exclusivity without requiring clinical superiority test; law codifying FDA policy passed prior to suit and is not retroactive.
You may also be interested in...
Viatris’ Mylan And Apotex Lose Again Over US Bendeka Patents
Viatris’ Mylan and Apotex once again fell to Teva and Eagle Pharmaceuticals in their battle to introduce generic versions of the rapid-infusion bendamustine formulation, Bendeka, with the US Federal Circuit upholding a lower court judgement.
A Matter Of Precedent: US FDA Sometimes Labors Under Weight Of Unpopular Or Unfavorable Decisions
As agency observers wonder whether and how political considerations will impact the timing of a COVID-19 vaccine approval or authorization, the Pink Sheet looks at instances through the years where agency staffers found themselves operating under precedents with which they disagreed or that didn’t work out as expected.
FDA's Orphan Drug Exclusivity Policy May Face Second Court Challenge
FDA denies seven years of orphan drug exclusivity for Eagle Pharmaceuticals' Bendeka (bendamustine) despite district court ruling in Depomed case rejecting agency's "clinical superiority" requirement.